{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T09:27:53Z","timestamp":1786786073616,"version":"build-2736575974"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:00:00Z","timestamp":1786752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:00:00Z","timestamp":1786752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300911"],"award-info":[{"award-number":["82300911"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-026-04757-7","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T07:50:58Z","timestamp":1786780258000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis"],"prefix":"10.1007","volume":"91","author":[{"given":"Qing-Xin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Jie","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9564-0961","authenticated-orcid":false,"given":"Fang-Yuan","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,15]]},"reference":[{"issue":"1","key":"4757_CR1","doi-asserted-by":"publisher","first-page":"80","DOI":"10.21037\/gs.2019.12.03","volume":"9","author":"OA Shariq","year":"2020","unstructured":"O.A. Shariq, T.J. McKenzie, Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery. Gland Surg. 9(1), 80\u201393 (2020)","journal-title":"Gland Surg."},{"issue":"6","key":"4757_CR2","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1161\/CIRCRESAHA.118.314487","volume":"124","author":"D Sun","year":"2019","unstructured":"D. Sun et al., Type 2 Diabetes and Hypertension. Circ. Res. 124(6), 930\u2013937 (2019)","journal-title":"Circ. Res."},{"issue":"2","key":"4757_CR3","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/inthealth\/ihad047","volume":"16","author":"X Zhang","year":"2024","unstructured":"X. Zhang et al., Prevalence of hypertension among type 2 diabetes mellitus patients in China: a systematic review and meta-analysis. Int. Health. 16(2), 144\u2013151 (2024)","journal-title":"Int. Health"},{"key":"4757_CR4","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2147\/DMSO.S503725","volume":"18","author":"MH Stanikzai","year":"2025","unstructured":"M.H. Stanikzai et al., Prevalence of Hypertension and Its Associated Factors Among Patients with Type 2 Diabetes in Southern Afghanistan: A Multi-Center Cross-Sectional Study. Diabetes Metab. Syndr. Obes. 18, 715\u2013725 (2025)","journal-title":"Diabetes Metab. Syndr. Obes."},{"issue":"1","key":"4757_CR5","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12889-022-12509-1","volume":"22","author":"H Alsaadon","year":"2022","unstructured":"H. Alsaadon et al., Hypertension and its related factors among patients with type 2 diabetes mellitus - a multi-hospital study in Bangladesh. BMC Public. Health. 22(1), 198 (2022)","journal-title":"BMC Public. Health"},{"issue":"9","key":"4757_CR6","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41371-021-00644-y","volume":"36","author":"E Shams","year":"2022","unstructured":"E. Shams et al., Highlights of mechanisms and treatment of obesity-related hypertension. J. Hum. Hypertens. 36(9), 785\u2013793 (2022)","journal-title":"J. Hum. Hypertens."},{"key":"4757_CR7","doi-asserted-by":"crossref","unstructured":"C.K. Wong, D.J. Drucker, Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits. J. Clin. Invest. 135(21), e194751 (2025)","DOI":"10.1172\/JCI194751"},{"issue":"2","key":"4757_CR8","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3803\/EnM.2024.1940","volume":"39","author":"JW Son","year":"2024","unstructured":"J.W. Son, S. Lim, Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management. Endocrinol. Metab. (Seoul). 39(2), 206\u2013221 (2024)","journal-title":"Endocrinol. Metab. (Seoul)"},{"key":"4757_CR9","doi-asserted-by":"publisher","first-page":"103363","DOI":"10.1016\/j.eclinm.2025.103363","volume":"86","author":"A Moiz","year":"2025","unstructured":"A. Moiz et al., The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions. EClinicalMedicine. 86, 103363 (2025)","journal-title":"EClinicalMedicine"},{"key":"4757_CR10","doi-asserted-by":"publisher","first-page":"1293926","DOI":"10.3389\/fcdhc.2023.1293926","volume":"4","author":"L Ferhatbegovi\u0107","year":"2023","unstructured":"L. Ferhatbegovi\u0107, D. Mr\u0161i\u0107, A. Maci\u0107-D\u017eankovi\u0107, The benefits of GLP1 receptors in cardiovascular diseases. Front. Clin. Diabetes Healthc. 4, 1293926 (2023)","journal-title":"Front. Clin. Diabetes Healthc."},{"issue":"9","key":"4757_CR11","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.3390\/biom15091342","volume":"15","author":"P Llongueras-Esp\u00ed","year":"2025","unstructured":"P. Llongueras-Esp\u00ed et al., Role of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) in Patients with Chronic Heart Failure. Biomolecules. 15(9), 1342 (2025)","journal-title":"Biomolecules"},{"key":"4757_CR12","doi-asserted-by":"publisher","first-page":"1004044","DOI":"10.3389\/fendo.2022.1004044","volume":"13","author":"B Gallwitz","year":"2022","unstructured":"B. Gallwitz, Clinical perspectives on the use of the GIP\/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Front. Endocrinol. (Lausanne). 13, 1004044 (2022)","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"12","key":"4757_CR13","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1111\/dom.15272","volume":"25","author":"M Kanbay","year":"2023","unstructured":"M. Kanbay et al., Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials. Diabetes Obes. Metab. 25(12), 3766\u20133778 (2023)","journal-title":"Diabetes Obes. Metab."},{"issue":"38","key":"4757_CR14","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1093\/eurheartj\/ehae564","volume":"45","author":"C Kennedy","year":"2024","unstructured":"C. Kennedy et al., Semaglutide and blood pressure: an individual patient data meta-analysis. Eur. Heart J. 45(38), 4124\u20134134 (2024)","journal-title":"Eur. Heart J."},{"key":"4757_CR15","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2147\/DMSO.S443396","volume":"17","author":"X Lv","year":"2024","unstructured":"X. Lv et al., The Effect of Tirzepatide on Weight, Lipid Metabolism and Blood Pressure in Overweight\/Obese Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetes Metab. Syndr. Obes. 17, 701\u2013714 (2024)","journal-title":"Diabetes Metab. Syndr. Obes."},{"issue":"1","key":"4757_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12933-023-01797-5","volume":"22","author":"I Lingvay","year":"2023","unstructured":"I. Lingvay et al., Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program. Cardiovasc. Diabetol. 22(1), 66 (2023)","journal-title":"Cardiovasc. Diabetol."},{"key":"4757_CR17","doi-asserted-by":"crossref","unstructured":"J.B. Buse et al., Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial. BMJ Open. Diabetes Res. Care 13(5), e005161(2025)","DOI":"10.1136\/bmjdrc-2025-005161"},{"issue":"5","key":"4757_CR18","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S2213-8587(24)00377-2","volume":"13","author":"T Kadowaki","year":"2025","unstructured":"T. Kadowaki et al., Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Lancet Diabetes Endocrinol. 13(5), 384\u2013396 (2025)","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"4757_CR19","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","volume":"5","author":"B Ahr\u00e9n","year":"2017","unstructured":"B. Ahr\u00e9n et al., Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 5(5), 341\u2013354 (2017)","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"4757_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"L.J. Aronne et al., Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. Jama. 331(1), 38\u201348 (2024)","journal-title":"Jama"},{"issue":"10489","key":"4757_CR21","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","volume":"405","author":"MP Bonaca","year":"2025","unstructured":"M.P. Bonaca et al., Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. LANCET. 405(10489), 1580\u20131593 (2025)","journal-title":"LANCET"},{"issue":"10278","key":"4757_CR22","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"M. Davies et al., Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet (london, england). 397(10278), 971\u2013984 (2021)","journal-title":"Lancet (london, england)"},{"issue":"15","key":"4757_CR23","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2017.14752","volume":"318","author":"M Davies","year":"2017","unstructured":"M. Davies et al., Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. Jama. 318(15), 1460\u20131470 (2017)","journal-title":"Jama"},{"issue":"10313","key":"4757_CR24","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","volume":"398","author":"S Del Prato","year":"2021","unstructured":"Del S. Prato et al., Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 398(10313), 1811\u20131824 (2021)","journal-title":"Lancet"},{"key":"4757_CR25","doi-asserted-by":"crossref","unstructured":"J.P. Frias et al., Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet (london, england). 392(10160), (2018)","DOI":"10.1016\/S0140-6736(18)32260-8"},{"issue":"10","key":"4757_CR26","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"W.T. Garvey et al., Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat. Med. 28(10), 2083\u20132091 (2022)","journal-title":"Nat. Med."},{"issue":"10402","key":"4757_CR27","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"402","author":"WT Garvey","year":"2023","unstructured":"W.T. Garvey et al., Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 402(10402), 613\u2013626 (2023)","journal-title":"Lancet"},{"issue":"9","key":"4757_CR28","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S2213-8587(22)00188-7","volume":"10","author":"N Inagaki","year":"2022","unstructured":"N. Inagaki et al., Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 10(9), 623\u2013633 (2022)","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"4757_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"A.M. Jastreboff et al., Tirzepatide Once Weekly for the Treatment of Obesity. N. Engl. J. Med. 387(3), 205\u2013216 (2022)","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"4757_CR30","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/dom.14232","volume":"23","author":"L Ji","year":"2021","unstructured":"L. Ji et al., Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial. Diabetes Obes. Metab. 23(2), 404\u2013414 (2021)","journal-title":"Diabetes Obes. Metab."},{"issue":"12","key":"4757_CR31","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"M.N. Kosiborod et al., Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N. Engl. J. Med. 389(12), 1069\u20131084 (2023)","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"4757_CR32","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"A.M. Lincoff et al., Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N. Engl. J. Med. 389(24), 2221\u20132232 (2023)","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"4757_CR33","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.2337\/dc17-2381","volume":"41","author":"I Lingvay","year":"2018","unstructured":"I. Lingvay et al., A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin. Diabetes Care. 41(9), 1926\u20131937 (2018)","journal-title":"Diabetes Care"},{"issue":"4","key":"4757_CR34","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"R. Loomba et al., Tirzepatide for Metabolic Dysfunction\u2013Associated Steatohepatitis with Liver Fibrosis. N. Engl. J. Med. 391(4), 299\u2013310 (2024)","journal-title":"N. Engl. J. Med."},{"issue":"10300","key":"4757_CR35","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","volume":"398","author":"B Ludvik","year":"2021","unstructured":"B. Ludvik et al., Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 398(10300), 583\u2013598 (2021)","journal-title":"Lancet"},{"issue":"13","key":"4757_CR36","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","volume":"391","author":"A Malhotra","year":"2024","unstructured":"A. Malhotra et al., Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N. Engl. J. Med. 391(13), 1193\u20131205 (2024)","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"4757_CR37","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"S.P. Marso et al., Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N. Engl. J. Med. 375(19), 1834\u20131844 (2016)","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"4757_CR38","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S2213-8587(24)00182-7","volume":"12","author":"BM McGowan","year":"2024","unstructured":"B.M. McGowan et al., Efficacy and safety of once-weekly semaglutide 2.4\u00a0mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Lancet Diabetes Endocrinol. 12(9), 631\u2013642 (2024)","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"12","key":"4757_CR39","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"P.N. Newsome et al., A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N. Engl. J. Med. 384(12), 1113\u20131124 (2021)","journal-title":"N. Engl. J. Med."},{"issue":"10148","key":"4757_CR40","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","volume":"392","author":"PM O\u2019Neil","year":"2018","unstructured":"P.M. O\u2019Neil et al., Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 392(10148), 637\u2013649 (2018)","journal-title":"Lancet"},{"issue":"5","key":"4757_CR41","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"M. Packer et al., Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N. Engl. J. Med. 392(5), 427\u2013437 (2025)","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"4757_CR42","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"V. Perkovic et al., Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N. Engl. J. Med. 391(2), 109\u2013121 (2024)","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"4757_CR43","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","volume":"6","author":"RE Pratley","year":"2018","unstructured":"R.E. Pratley et al., Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 6(4), 275\u2013286 (2018)","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"14","key":"4757_CR44","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"D. Rubino et al., Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. Jama. 325(14), 1414\u20131425 (2021)","journal-title":"Jama"},{"key":"4757_CR45","doi-asserted-by":"crossref","unstructured":"D.M. Rubino et al., Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults with Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 327(2), 138\u2013150 (2022).","DOI":"10.1001\/jama.2021.23619"},{"issue":"6","key":"4757_CR46","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.kint.2024.08.023","volume":"106","author":"V Selvarajah","year":"2024","unstructured":"V. Selvarajah et al., A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease. Kidney Int. 106(6), 1170\u20131180 (2024)","journal-title":"Kidney Int."},{"key":"4757_CR47","doi-asserted-by":"crossref","unstructured":"S. Wharton et al., Once-weekly semaglutide 7\u00b72\u00a0mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 13(11),949\u2013963 (2025)","DOI":"10.1016\/S2213-8587(25)00226-8"},{"key":"4757_CR48","unstructured":"A. Nct, Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05486065, 2022"},{"key":"4757_CR49","doi-asserted-by":"publisher","first-page":"1513641","DOI":"10.3389\/fendo.2025.1513641","volume":"16","author":"S Liu","year":"2025","unstructured":"S. Liu et al., Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with\/without type 2 diabetes: a systematic review and network meta-analysis. Front. Endocrinol. (Lausanne). 16, 1513641 (2025)","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"4757_CR50","doi-asserted-by":"crossref","unstructured":"C. Basile et al., Effect of Incretin-Based Therapies on Blood Pressure: A Systematic Review and Meta-Analysis. Eur. J. Prev. Cardiol. 33(7), 1210\u20131217 (2026)","DOI":"10.1093\/eurjpc\/zwaf560"},{"issue":"2","key":"4757_CR51","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40618-024-02459-3","volume":"48","author":"M Ala","year":"2025","unstructured":"M. Ala, M. Moheb, Aleaba, The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression. J. Endocrinol. Invest. 48(2), 283\u2013294 (2025)","journal-title":"J. Endocrinol. Invest."},{"issue":"3","key":"4757_CR52","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s12020-023-03636-9","volume":"83","author":"W Wu","year":"2024","unstructured":"W. Wu et al., The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis. Endocrine. 83(3), 571\u2013584 (2024)","journal-title":"Endocrine"},{"key":"4757_CR53","doi-asserted-by":"crossref","unstructured":"C. Kennedy et al., The Effect of Semaglutide on Blood Pressure in Patients without Diabetes: A Systematic Review and Meta-Analysis. J. Clin. Med. 12(3), 772 (2023)","DOI":"10.3390\/jcm12030772"},{"issue":"5","key":"4757_CR54","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s40256-025-00738-9","volume":"25","author":"Y Li","year":"2025","unstructured":"Y. Li et al., Meta-analysis of the Effect of Semaglutide on Blood Pressure in Obese Populations. Am. J. Cardiovasc. Drugs. 25(5), 655\u2013665 (2025)","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"11","key":"4757_CR55","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"J.P.H. Wilding et al., Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl. J. Med. 384(11), 989\u20131002 (2021)","journal-title":"N Engl. J. Med."},{"issue":"10","key":"4757_CR56","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"S.L. Kristensen et al., Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 7(10), 776\u2013785 (2019)","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"4757_CR57","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.diabres.2015.07.015","volume":"110","author":"F Sun","year":"2015","unstructured":"F. Sun et al., Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Res. Clin. Pract. 110(1), 26\u201337 (2015)","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"20","key":"4757_CR58","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1001\/jama.2023.19897","volume":"330","author":"A Elmaleh-Sachs","year":"2023","unstructured":"A. Elmaleh-Sachs et al., Obesity Management in Adults: A Review. Jama. 330(20), 2000\u20132015 (2023)","journal-title":"Jama"},{"issue":"5","key":"4757_CR59","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1161\/01.HYP.0000094221.86888.AE","volume":"42","author":"JE Neter","year":"2003","unstructured":"J.E. Neter et al., Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 42(5), 878\u2013884 (2003)","journal-title":"Hypertension"},{"issue":"4","key":"4757_CR60","first-page":"CD016144","volume":"4","author":"G Grenet","year":"2025","unstructured":"G. Grenet et al., Blood pressure lowering efficacy of dual glucose-dependent insulinotropic polypeptide\/glucagon-like peptide-1 (GIP\/GLP-1) receptor agonists compared to glucagon-like peptide-1 (GLP-1) receptor agonists. Cochrane Database Syst. Rev. 4(4), CD016144 (2025)","journal-title":"Cochrane Database Syst. Rev."},{"key":"4757_CR61","doi-asserted-by":"crossref","unstructured":"H.M. Yang, GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies. J Clin Med. 14(19), 6758 (2025).","DOI":"10.3390\/jcm14196758"},{"issue":"6","key":"4757_CR62","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"J.P. Fr\u00edas et al., Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl. J. Med. 385(6), 503\u2013515 (2021)","journal-title":"N Engl. J. Med."},{"key":"4757_CR63","doi-asserted-by":"publisher","first-page":"1570603","DOI":"10.3389\/fendo.2025.1570603","volume":"16","author":"F Koefoed-Hansen","year":"2025","unstructured":"F. Koefoed-Hansen et al., The evolution of the therapeutic concept \u2018GIP receptor antagonism\u2019. Front. Endocrinol. (Lausanne). 16, 1570603 (2025)","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"4","key":"4757_CR64","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.3390\/ijms21041509","volume":"21","author":"Y Mori","year":"2020","unstructured":"Y. Mori et al., GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease-A Systematic Review. Int. J. Mol. Sci. 21(4), 1509 (2020)","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"4757_CR65","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41591-024-03374-z","volume":"31","author":"BA Borlaug","year":"2025","unstructured":"B.A. Borlaug et al., Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. Nat. Med. 31(2), 544\u2013551 (2025)","journal-title":"Nat. Med."},{"issue":"6","key":"4757_CR66","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jama.2022.0078","volume":"327","author":"D Dahl","year":"2022","unstructured":"D. Dahl et al., Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. Jama. 327(6), 534\u2013545 (2022)","journal-title":"Jama"},{"issue":"7","key":"4757_CR67","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.cmet.2024.05.010","volume":"36","author":"A Regmi","year":"2024","unstructured":"A. Regmi et al., Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor. Cell. Metab. 36(7), 1534\u20131549e7 (2024)","journal-title":"Cell. Metab."},{"issue":"2","key":"4757_CR68","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","volume":"106","author":"MK Thomas","year":"2021","unstructured":"M.K. Thomas et al., Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J. Clin. Endocrinol. Metab. 106(2), 388\u2013396 (2021)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"4757_CR69","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1161\/01.HYP.30.5.1144","volume":"30","author":"E Ferrannini","year":"1997","unstructured":"E. Ferrannini et al., Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR). Hypertension. 30(5), 1144\u20131149 (1997)","journal-title":"Hypertension"},{"issue":"5","key":"4757_CR70","first-page":"671","volume":"36","author":"AA da Silva","year":"2020","unstructured":"da A.A. Silva et al., Role of Hyperinsulinemia and Insulin Resistance in Hypertension: Metabolic Syndrome Revisited. Can. J. Cardiol. 36(5), 671\u2013682 (2020)","journal-title":"Can. J. Cardiol."},{"issue":"10","key":"4757_CR71","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrneph.2017.123","volume":"13","author":"MHA Muskiet","year":"2017","unstructured":"M.H.A. Muskiet et al., GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat. Rev. Nephrol. 13(10), 605\u2013628 (2017)","journal-title":"Nat. Rev. Nephrol."},{"key":"4757_CR72","doi-asserted-by":"crossref","unstructured":"M. Writing Committee et al., AHA\/ACC\/AANP\/ Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 152(11), e114\u2013e218 (2025)","DOI":"10.1161\/CIR.0000000000001357"},{"issue":"1 Suppl 1","key":"4757_CR73","doi-asserted-by":"publisher","first-page":"S167","DOI":"10.2337\/dc25-S008","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee, 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2025. Diabetes Care. 48(1 Suppl 1), S167\u2013S180 (2025)","journal-title":"Diabetes Care"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04757-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04757-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04757-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T09:02:21Z","timestamp":1786784541000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04757-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,15]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4757"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04757-7","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,15]]},"assertion":[{"value":"8 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"275"}}